CENTRO DE INVESTIGACION BIOMEDICA EN RED ENFERMEDADES NEURODEGENERATIVAS

Their core work

CIBERNED is Spain's national biomedical research network dedicated exclusively to neurodegenerative diseases — Alzheimer's, Parkinson's, ALS, and related conditions. The network brings together research groups from across Spanish institutions, providing a coordinated infrastructure for basic and translational research into disease mechanisms, biomarkers, and therapeutic targets. In H2020, their contributions focused on two specific fronts: developing blood-based diagnostic tools for early-stage Alzheimer's disease, and investigating the purinergic P2X7 receptor as a target for controlling neuroinflammation. Their model as a research network means they offer distributed expertise across multiple labs rather than a single facility.

What they specialise in

How they've shifted over time

Both H2020 projects started in 2017 and ran through 2021, so there is no meaningful temporal shift visible within the available data — CIBERNED entered and exited H2020 in a single cohort of activity. No keyword data was captured for either project, which further limits trend analysis. Based on project titles alone, their focus was consistently on Alzheimer's and neuroinflammation throughout their H2020 participation, with no detectable pivot.

No directional shift is detectable from available data — both projects cover the same time window; a broader look at national funding records or their own publication output would be needed to assess where they are heading next.

How they like to work

CIBERNED has participated exclusively as a consortium partner, never as project coordinator, suggesting they contribute specialist expertise rather than driving project leadership. Both projects were large MSCA training networks — these consortia typically involve 10–15 partner institutions — which explains why 33 unique partners appear across just two projects. This points to a pattern of joining well-structured international networks rather than building bilateral collaborations.

CIBERNED has collaborated with 33 unique partners across 9 countries through two large MSCA training networks, giving them a broad European network despite a modest project count. Their partnerships are concentrated in the neuroscience and biomedical research communities rather than spread across sectors.

What sets them apart

CIBERNED's defining feature is its structure as a national research network rather than a single institution — it aggregates neurodegenerative disease expertise from multiple Spanish research groups under one organizational identity. For a consortium builder, this means a single partnership agreement can effectively bring in a breadth of Spanish neuroscience capacity. Their specific dual focus on diagnostics (BBDiag) and therapeutic targets (PurinesDX) also makes them a rare partner who can contribute to both the detection and treatment sides of neurodegeneration research.

Highlights from their portfolio

• BBDiag
  Addresses the critical unmet need for non-invasive early Alzheimer's diagnosis through blood biomarkers — a commercially high-value space with strong industry interest.
• PurinesDX
  Targets the P2X7 receptor, a mechanism with potential applications across multiple neuroinflammatory conditions beyond Alzheimer's, broadening translational relevance.